Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Key Inclusion Criteria: * Meets criteria for 1 of the 4 defined study cohorts * TNBC, defined as estrogen receptor (ER) and progesterone receptor (PR) negative (\< 1% by immunohistochemistry) and human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization \[FISH\] negative) * Metastatic disease or locally-advanced disease not amenable to curative intent treatment * Adequate hepatic, renal, cardiac, and hematologic function * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Recovery to baseline or ≤ Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version.4.0 Key Exclusion Criteria: * Known brain metastases or central nervous system (CNS) cancer unless adequately treated with radiotherapy and/or surgery and stable for ≥ 2 mo * Unable to receive oral medications * Known hypersensitivity to Cremophor®-based agents * Major surgery within 28 days of Cycle 1 Day 1